These innovative agents represent a significant advancement in the treatment of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates promising efficacy in controlling blood glucose https://aadamggie042018.dsiblogger.com/72063945/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide